Celldex Therapeutics reported $25.29M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Abbvie ABBV:US $ 6098M 3648M
Agenus AGEN:US $ 247.71M 44.22M
Amgen AMGN:US $ 6528M 1461M
Applied Genetic Technologies AGTC:US $ 67.85M 4.92M
Aptinyx Inc APTX:US $ 100.16M 5.96M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Celldex Therapeutics CLDX:US $ 25.29M 13.85M
Cytrx CYTR:US 5.08M 1.69M
Glaxosmithkline GSK:US $ 10967M 6693M
Immunogen IMGN:US $ 437.66M 41.09M
Merrimack Pharmaceuticals MACK:US $ 14.29M 91K
Nektar Therapeutics NKTR:US $ 67.99M 42.78M
Newlink Genetics NLNK:US $ 86.76M 8.05M
Northwest Biotherapeutics NWBO:US 6.96M 8.21M
Pfizer PFE:US $ 2470M 526M
Rigel Pharmaceuticals RIGL:US $ 24.68M 5.79M
Seattle Genetics SGEN:US $ 261M 163.84M